Skip to main content
. Author manuscript; available in PMC: 2017 Apr 14.
Published in final edited form as: Science. 2016 Sep 22;354(6309):237–240. doi: 10.1126/science.aai9137

Figure 1. ZIKV DNA vaccine design and characterization.

Figure 1

(A) Schematic representation of ZIKV genome and ZIKV DNA vaccine constructs VRC5283 and VRC5288. (B) Expression and secretion of ZIKV E was analyzed by Western blot of transfected 293T cell lysates and SVP precipitate pelleted from culture supernatants through a 20% sucrose cushion demonstrating that the VRC5288 construct secretes more particles than VRC5283. (C) Particle-capture ELISA quantifying the secretion of ZIKV SVP from transfected cells. (D) ZIKV subviral particles (SVP) were purified from the culture supernatant of VRC5288-transfected 293-F cells and subjected to negative staining and electron microscopy. SVP are labeled with arrowheads. The VRC8400 empty backbone plasmid vector was used as a control.